Cargando…

Modified Low-Dose Triiodo-L-thyronine Therapy Safely Improves Function Following Myocardial Ischemia-Reperfusion Injury

Background: We have shown that thyroid hormones (THs) are cardioprotective and can be potentially used as safe therapeutic agents for diabetic cardiomyopathy and permanent infarction. However, no reliable, clinically translatable protocol exists for TH treatment of myocardial ischemia-reperfusion (I...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajagopalan, Viswanathan, Zhang, Youhua, Pol, Christine, Costello, Clifford, Seitter, Samantha, Lehto, Ann, Savinova, Olga V., Chen, Yue-feng, Gerdes, A. Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388763/
https://www.ncbi.nlm.nih.gov/pubmed/28446882
http://dx.doi.org/10.3389/fphys.2017.00225
_version_ 1782521173501804544
author Rajagopalan, Viswanathan
Zhang, Youhua
Pol, Christine
Costello, Clifford
Seitter, Samantha
Lehto, Ann
Savinova, Olga V.
Chen, Yue-feng
Gerdes, A. Martin
author_facet Rajagopalan, Viswanathan
Zhang, Youhua
Pol, Christine
Costello, Clifford
Seitter, Samantha
Lehto, Ann
Savinova, Olga V.
Chen, Yue-feng
Gerdes, A. Martin
author_sort Rajagopalan, Viswanathan
collection PubMed
description Background: We have shown that thyroid hormones (THs) are cardioprotective and can be potentially used as safe therapeutic agents for diabetic cardiomyopathy and permanent infarction. However, no reliable, clinically translatable protocol exists for TH treatment of myocardial ischemia-reperfusion (IR) injury. We hypothesized that modified low-dose triiodo-L-thyronine (T3) therapy would confer safe therapeutic benefits against IR injury. Methods: Adult female rats underwent left coronary artery ligation for 60 min or sham surgeries. At 2 months following surgery and T3 treatment (described below), the rats were subjected to functional, morphological, and molecular examination. Results: Following surgery, the rats were treated with T3 (8 μg/kg/day) or vehicle in drinking water ad libitum following IR for 2 months. Oral T3 significantly improved left ventricular (LV) contractility, relaxation, and relaxation time constant, and decreased beta-myosin heavy chain gene expression. As it takes rats ~6 h post-surgery to begin drinking water, we then investigated whether modified T3 dosing initiated immediately upon reperfusion confers additional improvement. We injected an intraperitoneal bolus of T3 (12 μg/kg) upon reperfusion, along with low-dose oral T3 (4.5 μg/kg/day) in drinking water for 2 months. Continuous T3 therapy (bolus + low-dose oral) enhanced LV contractility compared with oral T3 alone. Relaxation parameters were also improved compared to vehicle. Importantly, these were accomplished without significant increases in hypertrophy, serum free T3 levels, or blood pressure. Conclusions: This is the first study to provide a safe cardiac therapeutic window and optimized, clinically translatable treatment-monitoring protocol for myocardial IR using commercially available and inexpensive T3. Low-dose oral T3 therapy supplemented with bolus treatment initiated upon reperfusion is safer and more efficacious.
format Online
Article
Text
id pubmed-5388763
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-53887632017-04-26 Modified Low-Dose Triiodo-L-thyronine Therapy Safely Improves Function Following Myocardial Ischemia-Reperfusion Injury Rajagopalan, Viswanathan Zhang, Youhua Pol, Christine Costello, Clifford Seitter, Samantha Lehto, Ann Savinova, Olga V. Chen, Yue-feng Gerdes, A. Martin Front Physiol Physiology Background: We have shown that thyroid hormones (THs) are cardioprotective and can be potentially used as safe therapeutic agents for diabetic cardiomyopathy and permanent infarction. However, no reliable, clinically translatable protocol exists for TH treatment of myocardial ischemia-reperfusion (IR) injury. We hypothesized that modified low-dose triiodo-L-thyronine (T3) therapy would confer safe therapeutic benefits against IR injury. Methods: Adult female rats underwent left coronary artery ligation for 60 min or sham surgeries. At 2 months following surgery and T3 treatment (described below), the rats were subjected to functional, morphological, and molecular examination. Results: Following surgery, the rats were treated with T3 (8 μg/kg/day) or vehicle in drinking water ad libitum following IR for 2 months. Oral T3 significantly improved left ventricular (LV) contractility, relaxation, and relaxation time constant, and decreased beta-myosin heavy chain gene expression. As it takes rats ~6 h post-surgery to begin drinking water, we then investigated whether modified T3 dosing initiated immediately upon reperfusion confers additional improvement. We injected an intraperitoneal bolus of T3 (12 μg/kg) upon reperfusion, along with low-dose oral T3 (4.5 μg/kg/day) in drinking water for 2 months. Continuous T3 therapy (bolus + low-dose oral) enhanced LV contractility compared with oral T3 alone. Relaxation parameters were also improved compared to vehicle. Importantly, these were accomplished without significant increases in hypertrophy, serum free T3 levels, or blood pressure. Conclusions: This is the first study to provide a safe cardiac therapeutic window and optimized, clinically translatable treatment-monitoring protocol for myocardial IR using commercially available and inexpensive T3. Low-dose oral T3 therapy supplemented with bolus treatment initiated upon reperfusion is safer and more efficacious. Frontiers Media S.A. 2017-04-12 /pmc/articles/PMC5388763/ /pubmed/28446882 http://dx.doi.org/10.3389/fphys.2017.00225 Text en Copyright © 2017 Rajagopalan, Zhang, Pol, Costello, Seitter, Lehto, Savinova, Chen and Gerdes. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Rajagopalan, Viswanathan
Zhang, Youhua
Pol, Christine
Costello, Clifford
Seitter, Samantha
Lehto, Ann
Savinova, Olga V.
Chen, Yue-feng
Gerdes, A. Martin
Modified Low-Dose Triiodo-L-thyronine Therapy Safely Improves Function Following Myocardial Ischemia-Reperfusion Injury
title Modified Low-Dose Triiodo-L-thyronine Therapy Safely Improves Function Following Myocardial Ischemia-Reperfusion Injury
title_full Modified Low-Dose Triiodo-L-thyronine Therapy Safely Improves Function Following Myocardial Ischemia-Reperfusion Injury
title_fullStr Modified Low-Dose Triiodo-L-thyronine Therapy Safely Improves Function Following Myocardial Ischemia-Reperfusion Injury
title_full_unstemmed Modified Low-Dose Triiodo-L-thyronine Therapy Safely Improves Function Following Myocardial Ischemia-Reperfusion Injury
title_short Modified Low-Dose Triiodo-L-thyronine Therapy Safely Improves Function Following Myocardial Ischemia-Reperfusion Injury
title_sort modified low-dose triiodo-l-thyronine therapy safely improves function following myocardial ischemia-reperfusion injury
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388763/
https://www.ncbi.nlm.nih.gov/pubmed/28446882
http://dx.doi.org/10.3389/fphys.2017.00225
work_keys_str_mv AT rajagopalanviswanathan modifiedlowdosetriiodolthyroninetherapysafelyimprovesfunctionfollowingmyocardialischemiareperfusioninjury
AT zhangyouhua modifiedlowdosetriiodolthyroninetherapysafelyimprovesfunctionfollowingmyocardialischemiareperfusioninjury
AT polchristine modifiedlowdosetriiodolthyroninetherapysafelyimprovesfunctionfollowingmyocardialischemiareperfusioninjury
AT costelloclifford modifiedlowdosetriiodolthyroninetherapysafelyimprovesfunctionfollowingmyocardialischemiareperfusioninjury
AT seittersamantha modifiedlowdosetriiodolthyroninetherapysafelyimprovesfunctionfollowingmyocardialischemiareperfusioninjury
AT lehtoann modifiedlowdosetriiodolthyroninetherapysafelyimprovesfunctionfollowingmyocardialischemiareperfusioninjury
AT savinovaolgav modifiedlowdosetriiodolthyroninetherapysafelyimprovesfunctionfollowingmyocardialischemiareperfusioninjury
AT chenyuefeng modifiedlowdosetriiodolthyroninetherapysafelyimprovesfunctionfollowingmyocardialischemiareperfusioninjury
AT gerdesamartin modifiedlowdosetriiodolthyroninetherapysafelyimprovesfunctionfollowingmyocardialischemiareperfusioninjury